{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T05:10:56Z","timestamp":1777525856635,"version":"3.51.4"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,12,23]],"date-time":"2021-12-23T00:00:00Z","timestamp":1640217600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100019331","name":"Henan Medical Science and Technique Foundation","doi-asserted-by":"publisher","award":["212300410403, 201701032"],"award-info":[{"award-number":["212300410403, 201701032"]}],"id":[{"id":"10.13039\/501100019331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background and Aims<\/jats:title><jats:p>This study investigated the feasibility, safety, and efficacy of transarterial chemoembolization (TACE) combined with CT-guided <jats:sup>125<\/jats:sup>iodine seed implantation for treatment of hepatocellular carcinoma (HCC) with first-branch portal vein tumor thrombosis (PVTT).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This prospective, controlled, multicenter study included HCC patients with Barcelona Clinic Liver Cancer stage C disease and PVTT in the right and\/or left portal veins. Patients were treated with either TACE and sorafenib or TACE and CT-guided <jats:sup>125<\/jats:sup>iodine seed implantation and regularly evaluated for clinical response and adverse events, with treatment termination resulting from declining clinical status, loss to follow-up, or death.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>This study demonstrated a significant between-group difference in median overall survival (OS); therefore, it was terminated early. A total of 123 patients were included in this study, with 52 patients in the TACE-sorafenib group and 71 patients in the TACE-<jats:sup>125<\/jats:sup>iodine group, without significant differences in baseline characteristics between groups. The median OS was 8.3 months (95% CI: 6.105\u201310.495) in the TACE-sorafenib group and 13.8 months (95% CI: 9.519\u201318.081) in the TACE-<jats:sup>125<\/jats:sup>iodine group. In a subgroup analysis of type IIa versus type IIb PVTT, the median OS was 17.5 months for type IIa and 7.1 months for IIb in the TACE-<jats:sup>125<\/jats:sup>iodine group. The median OS was 9.3 months for IIa and 4.0 months for IIb in the TACE-sorafenib group. Univariate and multivariate analyses confirmed that the PVTT type and treatment strategy were significant independent factors affecting OS. The objective response rates (ORR) for intrahepatic lesions and PVTT showed significant differences between groups. Most patients in both groups experienced minor adverse events related to TACE. The overall incidence of sorafenib-related adverse events or toxic effects was 90.4% in TACE-sorafenib group. In the TACE-<jats:sup>125<\/jats:sup>iodine group, the incidence of pneumothorax and minor hepatic subcapsular hemorrhage were 7.04% and 9.86%, respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This study showed that TACE-<jats:sup>125<\/jats:sup>iodine treatment significantly enhanced survival of patients with HCC and type II PVTT, especially subtype IIa, with minimal adverse events.<\/jats:p><\/jats:sec><jats:sec><jats:title>Clinical Trial Registration<\/jats:title><jats:p>Chinese Clinical Trials Database, identifier ChiCTR-ONN-16007929.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2021.806907","type":"journal-article","created":{"date-parts":[[2021,12,23]],"date-time":"2021-12-23T11:36:49Z","timestamp":1640259409000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":17,"title":["Hepatocellular Carcinoma With Portal Vein Tumor Thrombus Treated With Transarterial Chemoembolization and Sorafenib vs.125Iodine Implantation"],"prefix":"10.3389","volume":"11","author":[{"given":"Hong-Tao","family":"Hu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun-Peng","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guang-Shao","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhen","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen-Yang","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hang","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Quan-Jun","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiang","family":"Geng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jung-Hoon","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong-Tao","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun-Li","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hai-Liang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,12,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","article-title":"EASL Clinical Practice Guidelines: Management of Hepatocellular Carcinoma","volume":"69","year":"2018","journal-title":"J Hepatol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1002\/hep.29485","article-title":"Therapies for Patients With Hepatocellular Carcinoma Awaiting Liver Transplantation: A Systematic Review and Meta-Analysis","volume":"67","author":"Kulik","year":"2018","journal-title":"Hepatology"},{"key":"B3","doi-asserted-by":"publisher","first-page":"696","DOI":"10.5009\/gnl.2013.7.6.696","article-title":"Practical Effect of Sorafenib Monotherapy on Advanced Hepatocellular Carcinoma and Portal Vein Tumor Thrombosis","volume":"7","author":"Jeong","year":"2013","journal-title":"Gut Liver"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-018-3638-0","article-title":"Randomized, Prospective, Comparative Study on the Effects and Safety of Sorafenib vs. Hepatic Arterial Infusion Chemotherapy in Patients With Advanced Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis","volume":"82","author":"Choi","year":"2018","journal-title":"Cancer Chemother Pharmacol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvir.2011.03.005","article-title":"Chemoembolization for Hepatocellular Carcinoma: Multivariate Analysis of Predicting Factors for Tumor Response and Survival in a 362-Patient Cohort","volume":"22","author":"Hu","year":"2011","journal-title":"J Vasc Interv Radiol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2019181818","article-title":"Microvascular Invasion as a Predictor of Response to Treatment With Sorafenib and Transarterial Chemoembolization for Recurrent Intermediate-Stage Hepatocellular Carcinoma","volume":"292","author":"Peng","year":"2019","journal-title":"Radiology"},{"key":"B7","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1055\/s-0030-1247133","article-title":"Current Strategy for Staging and Treatment: The BCLC Update and Future Prospects","volume":"30","author":"Forner","year":"2010","journal-title":"Semin Liver Dis"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy308","article-title":"Hepatocellular Carcinoma: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up","volume":"29","author":"Vogel","year":"2018","journal-title":"Ann Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1007\/s00270-019-02406-3","article-title":"Hepatic Arterial Infusion Chemotherapy Using Oxaliplatin Plus 5-Fluorouracil Versus Transarterial Chemoembolization\/Embolization for the Treatment of Advanced Hepatocellular Carcinoma With Major Portal Vein Tumor Thrombosis","volume":"43","author":"Hu","year":"2020","journal-title":"Cardiovasc Intervent Radiol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.117.199752","article-title":"(90)Y Radioembolization for Locally Advanced Hepatocellular Carcinoma With Portal Vein Thrombosis: Long-Term Outcomes in a 185-Patient Cohort","volume":"59","author":"Abouchaleh","year":"2018","journal-title":"J\u00a0Nucl Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1666805","article-title":"Hepatocellular Carcinoma With Portal Vein Tumor Involvement: Best Management Strategies","volume":"38","author":"Liu","year":"2018","journal-title":"Semin Liver Dis"},{"key":"B12","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and Safety of Sorafenib in Patients in the Doubleblind, Placebo-Controlled Trial","volume":"10","author":"Cheng","year":"2009","journal-title":"Lancet Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2018171541","article-title":"Advanced Recurrent Hepatocellular Carcinoma: Treatment With Sorafenib Alone or in Combination With Transarterial Chemoembolization and Radiofrequency Ablation","volume":"287","author":"Peng","year":"2018","journal-title":"Radiology"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.14131946","article-title":"Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: Treatment With Transarterial Chemoembolization Combined With Sorafenib\u2013a Retrospective Controlled Study","volume":"272","author":"Zhu","year":"2014","journal-title":"Radiology"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2019-318934","article-title":"Randomised, Multicentre Prospective Trial of Transarterial Chemoembolisation (TACE) Plus Sorafenib as Compared With TACE Alone in Patients With Hepatocellular Carcinoma: TACTICS Trial","volume":"69","author":"Kudo","year":"2020","journal-title":"Gut"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1186\/1471-230X-13-60","article-title":"Transarterial Chemoembolization for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Meta Analysis","volume":"13","author":"Xue","year":"2013","journal-title":"BMC Gastroenterol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11070985","article-title":"Sorafenib With Transarterial Chemoembolization Achieves Improved Survival vs. Sorafenib Alone in Advanced Hepatocellular Carcinoma: A Nationwide Population-Based Cohort Study","volume":"11","author":"Kok","year":"2019","journal-title":"Cancers"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.09.010","article-title":"Molecular Therapies for HCC: Looking Outside the Box","volume":"72","author":"Faivre","year":"2020","journal-title":"J Hepatol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-013-1568-0","article-title":"Transarterial Chemoembolisation (TACE) Combined With Endovascular Implantation of an Iodine-125 Seed Strand for the Treatment of Hepatocellular Carcinoma With Portal Vein Tumour Thrombosis Versus TACE Alone: A Two-Arm, Randomised Clinical Trial","volume":"140","author":"Yang","year":"2014","journal-title":"J Cancer Res Clin Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.16491","article-title":"Transarterial Chemoembolization Combined With Computed Tomography-Guided 125iodine Implantation Enhances Survival in Hepatocellular Carcinoma Patients With Portal Vein Tumor Thrombus","volume":"8","author":"Hu","year":"2017","journal-title":"Oncotarget"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20933","article-title":"Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of Hepatocellular Carcinoma","volume":"42","author":"Bruix","year":"2005","journal-title":"Hepatology"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.7150\/jca.54650","article-title":"Safety and Efficacy of Drug-Eluting Bead Transarterial Chemoembolization With CalliSpheres\u00ae Microsphere for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Preliminary Study","volume":"12","author":"Zhou","year":"2021","journal-title":"J Cancer"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1002\/hep.30490","article-title":"An Eastern Hepatobiliary Surgery Hospital\/Portal Vein Tumor Thrombus Scoring System as an Aid to Decision Making on Hepatectomy for Hepatocellular Carcinoma Patients With Portal Vein Tumor Thrombus: A Multicenter Study","volume":"69","author":"Zhang","year":"2019","journal-title":"Hepatology"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-16-S13-S6","article-title":"An Adverse Event Capture and Management System for Cancer Studies","volume":"16","author":"Lencioni","year":"2015","journal-title":"BMC Bioinf"},{"key":"B25","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1055\/s-0030-1247132","article-title":"Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma","volume":"30","author":"Lencioni","year":"2010","journal-title":"Semin Liver Dis"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib Versus Sorafenib in first Line Treatment of Patients With Unresectable Hepatocellular Carcinoma: A Randomised Phase 3 Non-Inferiority Trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)30010-2","article-title":"Hepatocellular Carcinoma","volume":"391","author":"Forner","year":"2018","journal-title":"Lancet"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v19.i29.4679","article-title":"Hepatic Arterial Infusion Chemotherapy in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis","volume":"19","author":"Song","year":"2013","journal-title":"World J Gastroenterol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2017.11.013","article-title":"Comparison of Radiation Therapy Modalities for Hepatocellular Carcinoma With Portal Vein Thrombosis: A Meta-Analysis and Systematic Review","volume":"129","author":"Rim","year":"2018","journal-title":"Radiother Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2017.11.013","article-title":"Efficacy and Safety of Transarterial Chemoembolization Plus External Beam Radiotherapy vs Sorafenib in Hepatocellular Carcinoma With Macroscopic Vascular Invasion: A Randomized Clinical Trial","volume":"4","author":"Yoon","year":"2018","journal-title":"JAMA Oncol"},{"key":"B31","article-title":"The Impact of Combined Transarterial Chemoembolization on the Overall Survival of Patients With Advanced Hepatocellular Carcinoma Treated With Sorafenib","volume":"61","author":"Chen","year":"2014","journal-title":"Hepatogastroenterology"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13122912","article-title":"Is the Concurrent Use of Sorafenib and External Radiotherapy Feasible for Advanced Hepatocellular Carcinoma? A Meta-Analysis","volume":"13","author":"Rim","year":"2021","journal-title":"Cancers (Basel)"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.806907\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,23]],"date-time":"2021-12-23T11:36:51Z","timestamp":1640259411000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.806907\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,23]]},"references-count":32,"alternative-id":["10.3389\/fonc.2021.806907"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2021.806907","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,23]]},"article-number":"806907"}}